Last reviewed · How we verify
L-Cystine (CYSTINE)
At a glance
| Generic name | CYSTINE |
|---|---|
| Drug class | Vitamin C [EPC] |
| Modality | Small molecule |
| Therapeutic area | Other |
| Phase | FDA-approved |
Approved indications
- Immune Deficiency Support
Common side effects
Key clinical trials
- Efficacy and Safety of Millet Seed Extract in Telogen Effluvium Treatment (NA)
- Use of Cysteamine in the Treatment of Cystinosis
- Optimizing Treatment of Co-occurring Smoking and Unhealthy Alcohol Use Among PWH in Nairobi, Kenya (PHASE3)
- The Effect of Sodium-glucose Cotransporter (SGLT) 2 Inhibitors on Cystine Stone Formation: A Preliminary Study (PHASE2)
- Prandial Metabolic Phenotype in Adults (NA)
- Mitochondrial Capacity Boost in ALS (MICABO-ALS) Trial (PHASE2)
- Rare Kidney Stone Consortium Patient Registry
- The Impact of a Nutritional Supplement (Impryl®) on Male Fertility (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- L-Cystine CI brief — competitive landscape report
- L-Cystine updates RSS · CI watch RSS